Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Satu Koivula"'
Autor:
Minna Taskinen, Riku Louhimo, Satu Koivula, Ping Chen, Ville Rantanen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Björkholm, Øystein Fluge, Lars Møller Pedersen, Karin Fjordén, Mats Jerkeman, Mikael Eriksson, Sampsa Hautaniemi, Sirpa Leppä
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91031 (2014)
Despite improved survival for the patients with diffuse large B-cell lymphoma (DLBCL), the prognosis after relapse is poor. The aim was to identify molecular events that contribute to relapse and treatment resistance in DLBCL.We analysed 51 prospecti
Externí odkaz:
https://doaj.org/article/760556e9d79c4d1f8fbe71cf2f3c2120
Publikováno v:
Modern Pathology. 23:686-693
Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-beta and AKT pathways. To determine whether protein kinase C-be
Autor:
Mats Jerkeman, Lars Moller Pedersen, Riku Louhimo, Øystein Fluge, Marja-Liisa Karjalainen-Lindsberg, Ville Rantanen, Satu Koivula, Minna Taskinen, Jan Delabie, Sampsa Hautaniemi, Mikael Eriksson, Magnus Björkholm, Sirpa Leppä, Harald Holte, Karin Fjordén, Ping Chen
Publikováno v:
PLoS ONE
Taskinen, M, Louhimo, R, Koivula, S, Chen, P, Rantanen, V, Holte, H, Delabie, J, Karjalainen-Lindsberg, M L, Bjorkholm, M, Fluge, O, Pedersen, L M, Fjorden, K, Jerkeman, M, Eriksson, M, Hautaniemi, S & Leppa, S 2014, ' Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma ', P L o S One, vol. 9, no. 3, e91031 . https://doi.org/10.1371/journal.pone.0091031
PLoS ONE, Vol 9, Iss 3, p e91031 (2014)
PLoS ONE; 9(3), no e91031 (2014)
Taskinen, M, Louhimo, R, Koivula, S, Chen, P, Rantanen, V, Holte, H, Delabie, J, Karjalainen-Lindsberg, M L, Bjorkholm, M, Fluge, O, Pedersen, L M, Fjorden, K, Jerkeman, M, Eriksson, M, Hautaniemi, S & Leppa, S 2014, ' Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma ', P L o S One, vol. 9, no. 3, e91031 . https://doi.org/10.1371/journal.pone.0091031
PLoS ONE, Vol 9, Iss 3, p e91031 (2014)
PLoS ONE; 9(3), no e91031 (2014)
Background: Despite improved survival for the patients with diffuse large B-cell lymphoma (DLBCL), the prognosis after relapse is poor. The aim was to identify molecular events that contribute to relapse and treatment resistance in DLBCL. Methods: We
Publikováno v:
Oncology Reports. 25
Rituximab, a CD20-specific antibody, is used with chemotherapy as a treatment for diffuse large B cell lymphoma (DLBCL). Although many patients benefit from the addition of rituximab to chemotherapy, a favourable response is not achieved in approxima
Autor:
Alejandra Cervera, Minna Taskinen, Satu Koivula, Jan Delabie, Sampsa Hautaniemi, Sirpa Leppä, Harald Holte, Marja-Liisa Karjalainen-Lindsberg, Ping Chen
Publikováno v:
University of Helsinki
Abstract 1557 Background: The aim was to compare differentially expressed exons and splicing variants between diffuse large B-cell lymphoma (DLBCL) patients, who had relapsed or remained in remission after dose dense chemoimmunotherapy. Design and me
Autor:
Sirpa Leppä, Satu Koivula, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Harald Holte, Sampsa Hautaniemi, Magnus Björkholm, Minna Taskinen, Ping Chen, Riku Louhimo, Lars Moeller Pedersen, Øystein Fluge, Mats Jerkeman, Karin Rydström, Mikael Eriksson
Publikováno v:
Journal of Clinical Oncology. 30:8074-8074
8074 Background: Identification of biological prognostic factors that could be used to define poor risk diffuse large B-cell lymphoma (DLBCL) patients is a main concern. Methods: Study population consisted of 38 de novo high risk DLBCL patients less
Autor:
Jan Delabie, Satu Koivula, Sampsa Hautaniemi, Magnus Björkholm, Mats Jerkeman, Minna Taskinen, Marja-Liisa Karjalainen-Lindsberg, Lars Moller Pedersen, Mikael Eriksson, Sirpa Leppä, Harald Holte, Ping Chen, Øystein Fluge
Publikováno v:
Blood. 116:3107-3107
Abstract 3107 Background: Survival of young high risk diffuse large B-cell lymphoma (DLBCL) is now approaching 80% due to implementation of rituximab and dose-dense chemotherapy protocols but the patients with relapsed or refractory disease continue
Autor:
Sirpa Leppä, Minna Taskinen, Satu Koivula, Ping Chen, Riku Louhimo, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moeller Pedersen, Karin Rydstrom, Mats Jerkeman, Mikael Eriksson, Sampsa Kalervo Hautaniemi, Harald Holte, Nordic Lymphoma Grp
Publikováno v:
University of Helsinki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0afdb5e4ea5302bc21e2eb02d3e3dad5
https://researchportal.helsinki.fi/en/publications/e619d1d4-5648-4ba5-b93b-5c95d2462edc
https://researchportal.helsinki.fi/en/publications/e619d1d4-5648-4ba5-b93b-5c95d2462edc
Autor:
Satu Koivula, Minna Taskinen, Ping Chen, Harald Holte, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sampsa Kalervo Hautaniemi, Sirpa Leppä
Publikováno v:
University of Helsinki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::428b7b3ce7c9914ecf9d0629fd2bcdd6
https://researchportal.helsinki.fi/en/publications/14916124-5524-44d2-814e-1b4ef4c3a00e
https://researchportal.helsinki.fi/en/publications/14916124-5524-44d2-814e-1b4ef4c3a00e